A Phase 1 trial assessing how cudetaxestat, an investigational treatment for idiopathic pulmonary fibrosis (IPF), interacts with two approved IPF treatments, …
Articles by Patricia Inácio, PhD
Treatment with N115, EmphyCorp’s non-steroidal nasal spray, led to statistically and clinically significant improvements across all lung function parameters in…
Long-term exposure to air pollutants — nitrogen dioxide, ozone, and fine particle matter — appears to greatly raise the risk of…
A large and multi-ethnic database, reported to be the first of its kind for rare lung diseases, is now compiling…
Interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), are associated with a substantial economic burden to healthcare systems…
The Three Lakes Foundation is joining with the Lung Foundation Australia, the Centre of Research Excellence in…
More than 100,000 fewer hospital appointments were logged by people with lung diseases like idiopathic pulmonary fibrosis (IPF) in…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will…
As part of the worldwide commemoration of Clinical Trials Day, held each year on May 20, the Pulmonary Fibrosis…
People with idiopathic pulmonary fibrosis (IPF) who live in poorer neighborhoods are less likely to receive a lung…